Atlanta – (work wire) – Verius Therapeutics Inc. (Nasdaq: ferry), a development-stage biotechnology company focused on developing new, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, today announced the results of a pilot study conducted at the University of Alabama, titled “Herpes simplex virus type 1 infection of the stomach Associated with functional gastrointestinal disorders in the presence and absence of concomitant fibromyalgia: a case-control pilot study,” published in the journal infection. These results provide evidence for a possible mechanistic link between active herpes virus infection and functional gastrointestinal disorders (“FGID”), with or without associated fibromyalgia (“FM”), as well as the potential for combination antiviral therapy to treat patients with FGIDs and FM.
In this study, tissue biopsies were obtained from three groups of volunteers: the first group was those with FGID, such as irritable bowel syndrome, functional dyspepsia, functional constipation as well as MS. Group 2 was with FGID only; and group 3 were control patients without FGID or FM. Epidemiological studies indicate that FM affects approximately 2% of the population. Previous research has been published in Gastrointestinal Diseases In 2021, it was found that FGIDs affect 40% of people worldwide and affect quality of life and health care use. Neither histological gastritis nor Germ stomach The infection was found to be associated with FGIDs or FM.
“The data provided by Dr. Duffy were from a tissue biopsy study conducted jointly by the University of Alabama and Virios Therapeutics,” commented R. Michael Gendreau, Ph.D., chief medical officer of Virios Therapeutics. The study examined gastric mucosal biopsies from three groups: patients with FGID, patients with FGID and FM, and control patients. Biopsy samples were analyzed for the presence of active herpes virus infection. As discussed in the publication, there was a significant increase in the presence of actively recurrent herpes simplex virus type 1 (“HSV-1”) in the gastric mucosal tissues of the FGID, FGID, and FM patient groups compared to the control patients. ”
“This finding highlights the potential role of activated HSV-1 as a possible root cause of common chronic gastrointestinal disorders. Importantly, neither histological gastritis nor Germ stomach The infection was found to be associated with FGIDs or FM. This publication provides further clarity to the medical community about the potential benefit of a combination of antiviral drug therapies, such as IMC-1, for patients with chronic conditions such as FM and irritable bowel syndrome (“IBS”), which are often described as functional disorders,” concluded Dr. Gendreau.
Title: Herpes simplex virus type 1 infection is associated with functional gastrointestinal disturbances in the presence and absence of associated fibromyalgia: a case-control pilot study.
Authors: Carol Duffy, Ph.D., Department of Biological Sciences, University of Alabama, Tuscaloosa, Alabama; William Bridgen, MD, Tuscaloosa Surgical Associates; Rich Whiteley, MD, Division of Pediatric Infectious Diseases, Department of Pediatrics, Hersink College of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
Conclusions: Analysis of gastric mucosal biopsies revealed a significant positive association between active gastric HSV-1 recurrence and multiple functional gastrointestinal disorders, with or without concomitant FM. FGIDs including IBS, functional dysphagia and functional dyspepsia may be related to active HSV-1 infection. Further investigation into the prevalence and possible causal nature of this association is warranted.
For more information, please visit www.virios.com.
About VIRUS Therapeutics
Virios Therapeutics (Nasdaq: VIRI) is a development-stage biotechnology company focused on developing new antiviral therapies to treat debilitating chronic diseases, such as fibromyalgia (FM). Immune responses related to activation of tissue herpes have been postulated as a possible root cause that causes and/or maintains chronic diseases such as FM, irritable bowel disease, chronic fatigue syndrome, and other somatic functional syndromes, all of which are characterized by waxing and/or persistence. Symptoms diminish with no apparent etiology. Our lead development candidate (“IMC-1”) is a new, proprietary, fixed-dose combination of famciclovir and celecoxib designed to synergistically suppress replication of herpes virus, with the ultimate goal of reducing virally-stimulated disease symptoms. IMC-1 has been granted fast-track designation by the Food and Drug Administration and is currently being tested in a multicenter, randomized, double-blind, placebo-controlled trial (“FORTRESS”), designed to serve as a supportive registry study. Evidence for the efficacy of IMC-1 on a wide range of FM outcome measures was previously demonstrated in a phase 2a clinical trial.
The company is seeking to develop a second candidate, IMC-2 (valacyclovir and celecoxib), as a potential treatment for the management of fatigue, sleep, alertness, pain, autonomic function and anxiety associated with prolonged COVID-19, also known as the post-acute sequelae of COVID-19 (PASC). The Company provided the Pitman Horn Center (“BHC”) an unrestricted grant to conduct this study. BHC is a not-for-profit, multidisciplinary center of excellence that advances the diagnosis and treatment of chronic fatigue disorders, FM syndromes, postviral syndromes, and related comorbidities.
For more information, please visit www.virios.com.
Follow Virios Therapeutics
Statements in this press release contain “forward-looking statements,” within the meaning of the US Securities Litigation Reform Act of 1995, that are subject to significant risks and uncertainties. All statements, other than statements of historical facts, contained in this press release are forward-looking statements. The forward-looking statements made in this press release may be identified by the use of words such as “expect,” “believe,” “think,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” may,” “plan,” “potential,” “expect,” “project,” “goal,” “aimed,” “should,” “will,” “will,” or the negative of these or other similar expressions, Although not all forward-looking statements contain these words.Forward-looking statements are based on Virios Therapeutics’ current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict, including risks related to the success, cost, and timing of Virios Therapeutics’ preclinical studies and clinical trials; their ability to obtain on the regulatory approval of IMC-1 and IMC-2 and any future candidate product the Company’s need for additional financing and Virios Therapeutics’ ability to develop and market its candidate products if approved.Moreover, certain forward-looking statements are based on assumptions regarding future events that may Not be accurate These risks and other uncertainties are fully described in the section titled “Pain Factors.” Thoughts” in the annual report on Form 10-K for the year ended December 31, 2021 and filed with the Securities and Exchange Commission. The forward-looking statements contained in this announcement are made as of this date, and Virios Therapeutics, Inc. (VIRI) has no duty to update this information except as required by applicable law.